Castration-resistant Prostate Cancer
Conditions
Keywords
Metastatic Castration-resistant prostate cancer., HER2- expression
Brief summary
The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.
Detailed description
This is a Multicenter Open Phase II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Disitamab Vedotin in the Treatment With HER2- Expression, Subjects with locally advanced or metastatic castration-resistant prostate cancer. The study plans to enroll 40 subjects with locally advanced or metastatic CRPC with HER2 expression (IHC 1+ and above) who have been treated with androgen deprivation therapy and novel hormone therapy. Eligible subjects were enrolled and received RC48 intravenous infusion at a dose of 2.0 mg/kg every 2 weeks. Subjects received medication until disease progression, intolerable toxicity, active withdrawal, death, or study termination by the sponsor.
Interventions
2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
Sponsors
RemeGen Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Pathology confirmed prostate adenocarcinoma 3. Locally advanced or metastatic prostate cancer 4. PCWG3 criteria-compliant prostate cancer progression occurs during androgen deprivation therapy (or bilateral scrotal excision). Progression will be determined based on at least 1 of the following criteria: PSA progression: defined as 2 consecutive increases in PSA, separated by at least 1 week, relative to the previous reference value. If a confirmed PSA increase is the only indicator of progression, then 1 ng/mL is the minimum starting value; Soft tissue progression: defined as an increase of ≥20% in the sum of the diameters of all target lesions (short-axis for lymph node lesions and long-axis for non-lymph node lesions) relative to the sum of the smallest diameters at the start of treatment or the presence of one or more new lesions; Bone lesion progression: defined as the detection of at least two additional new lesions on bone scan. 5. Serum testosterone level ≤ 50 ng/dL (or ≤ 1.73 nmol/L), prior to the first study drug administration; 6. Continuous androgen deprivation therapy (ADT) with LHRH agonists or LHRH antagonists or previous bilateral orchiectomy (surgical debridement) during the study period; 7. Confirmed HER2 expression (IHC 1+, 2+, 3+), HER2 gene amplification, or HER2 gene mutation; 8. Subjects were able to provide paraffin blocks or at least 5 paraffin embedded sections (white pieces) for HER2 detection, and the presence of HER2 expression was confirmed by central laboratory tests (immunohistochemistry 1+, 2+, 3+)； 9. Previous medical androgen deprivation therapy (or bilateral scrotal excision) and new hormone therapy (e.g. abiraterone, enzalutamide) and have developed disease progression 10. The following criteria should be met within 7 days prior to the first study dose: 1. haemoglobin ≥ 9 g/dL; 2. absolute neutrophil count (ANC) ≥ 1.5 × 109/L; 3. platelet count ≥ 100 × 109/L; 4. serum total bilirubin ≤ 1.5 times the upper limit of normal (ULN); 5. without liver metastasis, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN; with liver metastasis, alanine aminotransferase and aspartate aminotransferase ≤ 5 × ULN;; 6. albumin (ALB) ≥ 25 g/L; 7. blood creatinine ≤ 1.5 × ULN, or calculated according to the Cockcroft-Gault formula, creatinine clearance (CrCl) ≥ 50 mL/min; 8. left ventricular ejection fraction (LVEF) ≥ 50%; 11. ECOG Physical Status Score of 0-1 12. Expected survival ≥ 6 months 13. Subjects whose spouses are of childbearing age must agree to use contraception during the study and for 6 months after the last dose; sperm donation is not permitted during the study and for 6 months after the last dose 14. Ability to understand and sign an informed consent form.
Exclusion criteria
1. Systematic chemotherapy, novel hormone therapy, targeted therapy, immunotherapy, or other antitumor therapy (including 5-alpha reductase inhibitors, oestrogens, and medroxyprogesterone, etc.)was administered prior to the initial study drug, and treatment ended within 5 half-lives (or 2 weeks, whichever is shorter) of the initial study drug. Except maintenance castration therapy (LHRH agonists or LHRH antagonists) or bone metastasis therapy(e.g., denosumab, zoledronic acid); In the first study, Chinese medicines with anti-tumor indications were used 2 weeks before administration. 2. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis (subjects who have been treated for brain metastases may be enrolled in this study provided they have stable disease \[no evidence of progression as determined by imaging for at least 4 weeks prior to study dosing and and all neurological symptoms have fully recovered\], there is no evidence of new or enlarging brain metastases, and discontinuation of steroid therapy at least 7 days prior to the first dose of the trial treatment. (This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable or not). 3. Has received anti-HER2 therapy ; 4. Major surgery, systemic radiotherapy or biologic therapy within 4 weeks prior to first study drug administration, or minor surgery or local radiotherapy within 1 week prior to enrollment; 5. Toxicity due to prior antineoplastic therapy that has not recovered to Common Terminology Criteria for Adverse Events (CTCAE Version 5.0) Grade 1 or below, with the exception of alopecia and abnormalities in laboratory tests or toxicity associated with LHRH agonists or LHRH antagonists that are not considered by the investigator to pose a safety risk; 6. Known allergic reactions to components of the study treatment or its analogues 7. Diagnosis of other malignancies that are expected to affect life expectancy or may interfere with disease assessment. Except for cured non-melanoma skin cancer and superficial bladder cancer 8. Severe and/or persistent infection within 14 days prior to starting the study drug 9. Serum virological tests: positive HBsAg test result with a positive HBV DNA copy number; positive HCVAb test result; positive HIVAb test result; 10. Known serious cardiovascular disease, including any of the following: myocardial infarction, thrombotic event, or unstable angina pectoris in the past 3 months; chronic heart failure, New York Heart Association (NYHA) class II or higher; presence of unstable arrhythmia; uncontrolled hypertension; 11. Combined grade 2 and higher (CTCAE version 5.0) peripheral neuropathy 12. Presence of other systemic diseases that, in the judgement of the investigator, are not under stable control, including diabetes mellitus, liver cirrhosis, pneumonitis, and obstructive pulmonary disease; 13. In the judgement of the investigator, there were other circumstances that made participation in the study unsuitable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic progression free survival，rPFS | Up to approximately 2 years | Define imaging disease progression according to RECIST v1.1 (for all lesions except bone lesions) or PCWG3 (for bone lesions) as the time from the first dose of the drug to the time when the imaging shows disease progression or death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate (ORR) | Up to approximately 2 years | ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1) |
| Disease Control Rate (DCR) | Until progression, assessed up to approximately 2 years | Percentage of patients with complete response, partial response, or stable disease for a certain period of time according to RECIST v1.1. |
| Time to PSA progression(TTPP) | Until progression, assessed up to approximately 2 years | Defined as time from date of first dose to first PSA progression |
| Duration of response (DoR) | Until progression, assessed up to approximately 2 years | Defined as the time from the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression by Investigators assessment according to RECIST 1.1 |
| PSA response rate | Until progression, assessed up to approximately 2 years | Percent of subjects with different degree of decrease in PSA compared to baseline |
| Time to first symptomatic bone-related event (SSE) | Until progression, assessed up to approximately 2 years | Defined as the time from the first dose to the first occurrence of SSE. |
| Incidence of ECG abnormalities | Up to follow-up period, approximately 2 years | To be summarized using descriptive statistics |
| Cmax of RC48 | Up to approximately 2 years | Peak Plasma Concentration of RC48 |
| AUC of RC48 | Up to approximately 2 years | Area under the plasma concentration versus time curve of RC48 |
| AUC of MMAE | Up to approximately 2 years | Area under the plasma concentration versus time curve of MMAE |
| Immunogenicity of RC48 | up to approximately 2 years | Anti-drug antibody (ADA) of RC48 positive samples, etc. |
| Percentage of Participants With Adverse Events (AEs) | Up to approximately 2 years | Number of participants with adverse effects of treatment. Frequency and severity of adverse effects of treatment as assessed by NCI CTCAE v5.0 |
| Incidence of laboratory tests abnormalities | Up to follow-up period, approximately 2 years | To be summarized using descriptive statistics |
| Overall Survival (OS) | Up to approximately 2 years | OS was defined as the time from the date of randomization to the date of death from any cause. |
Countries
China
Contacts
Primary ContactJianmin Fang, Ph.D
Outcome results
None listed